For example, a patient who is 65 years old and received the QIV instead of the recommended aTIV:
Follow the process in PHE’s recently updated Inactivated influenza vaccine guidance for healthcare practitioners:
Inform the patient of the error and its potential implications
Advise the patient that although the QIV and aTIV will offer some protection to all age groups, individuals aged 65 years and over (particularly those more than 75 years of age) may not respond as well to the QIV as they would to the aTIV, and individuals aged under 65 years will not benefit from the opportunity to make protection against an additional flu strain if they have been given aTIV;
Following a discussion about the risks and benefits, advise the patient that they could, if they wish, be given a second dose of the vaccine they should have had
The clear benefit is the additional protection that may be offered by the correct vaccine, but they should be alerted to the potential increased risk of a local or systemic reaction. Although there is no data available on the safety and effectiveness of administering a second flu vaccine shortly after the first in adults, this advice is based on general principles of vaccination, experience of flu revaccination following cold chain and administration incidents and information about the high dose flu vaccine used in the United States (which contains four times the amount of antigen that is in a single dose of QIV or aTIV).
If a decision is made to offer the vaccine the patient should have received, it is recommended that this is done as soon as possible after the first dose was given and ideally within a week. This will enable protection to be made as soon as possible. It can, however, still be given if more than a week has elapsed.
This advice also applies to those who have inadvertently been given non-adjuvanted trivalent influenza vaccine (TIV).
Patient Leaflet – coming back to the pharmacy for your flu jab